ELEVATED SERUM LEVELS OF SOLUBLE INTERLEUKIN-2 RECEPTOR IN PATIENTS WITH WEGENERS GRANULOMATOSIS - ASSOCIATION WITH DISEASE-ACTIVITY

被引:142
作者
SCHMITT, WH
HEESEN, C
CSERNOK, E
RAUTMANN, A
GROSS, WL
机构
[1] UNIV LUBECK,DEPT RHEUMATOL,LUBECK,GERMANY
[2] CTR RHEUMATOL,BAD BRAMSTEDT,GERMANY
来源
ARTHRITIS AND RHEUMATISM | 1992年 / 35卷 / 09期
关键词
D O I
10.1002/art.1780350914
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To investigate whether soluble interleukin-2 receptor (sIL-2R), a marker of T cell activation, could be a useful marker of disease activity in Wegener's granulomatosis (WG). Methods. Soluble IL-2R levels were determined by enzyme-linked immunosorbent assay. WG disease activity in 102 patients was assessed according to clinical features and levels of classic antineutrophil cytoplasmic antibody (c-ANCA) and C-reactive protein (CRP). Results. Soluble IL-2R levels were higher in patients with generalized and active disease than in those with limited and inactive disease. In 25 patients with complete clinical remission, sIL-2R levels were significantly elevated, although levels of CRP and c-ANCA were normal. Eight of these 25 patients had disease relapses within 6 months. Levels of sIL-2R were significantly higher in patients who had relapses than in those who did not. Patients with clinically active WG but low c-ANCA or CRP levels had elevated levels of sIL-2R. Conclusion. Levels of sIL-2R correlate with disease activity in patients with WG, and may indicate imminent relapse.
引用
收藏
页码:1088 / 1096
页数:9
相关论文
共 40 条
[1]  
ANDRASSY K, 1989, CLIN NEPHROL, V32, P159
[2]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[3]  
BALDERAS RS, 1987, J IMMUNOL, V139, P1496
[4]   INFECTIOUS COMPLICATIONS OF CYCLOPHOSPHAMIDE TREATMENT FOR VASCULITIS [J].
BRADLEY, JD ;
BRANDT, KD ;
KATZ, BP .
ARTHRITIS AND RHEUMATISM, 1989, 32 (01) :45-53
[5]  
BROUWER E, 1991, KIDNEY INT, V39, P1055
[6]  
DEGUCHI Y, 1990, CLIN EXP IMMUNOL, V81, P311
[7]  
DEREMEE RA, 1976, MAYO CLIN PROC, V51, P777
[8]   WEGENERS GRANULOMATOSIS - PROSPECTIVE CLINICAL AND THERAPEUTIC EXPERIENCE WITH 85 PATIENTS FOR 21 YEARS [J].
FAUCI, AS ;
HAYNES, BF ;
KATZ, P ;
WOLFF, SM .
ANNALS OF INTERNAL MEDICINE, 1983, 98 (01) :76-85
[9]  
GRAU GE, 1989, IMMUNOLOGY, V68, P196
[10]  
Gross W L, 1989, Sarcoidosis, V6, P15